All News

We all survived another October and the tidal wave of pink that represents breast cancer.

Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.

Giving thanks for cancer is a choice, and a difficult one at that. How can one give thanks for something so painful and traumatizing?

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION ANNOUNCES NEW EXECUTIVE DIRECTOR

The Food and Drug Administration granted a priority review to Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for the frontline treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing, according to Roche, the drug’s manufacturer.

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Given their proximity to both patients and information, lung cancer advocacy groups are in a good position to help better educate patients and physicians about the benefits of biomarker testing.

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

Making predictions on how cancer will affect your life from diagnosis to post treatment is a waste of time. No one knows what tomorrow will bring.

Lock Up Lung Cancer is a new campaign to expose the disease as a prolific killer, according to LUNG FORCE.

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

At a local event, Shannon Pulaski – author of Mom’s Genes – shared her journey after being diagnosed with the BRCA mutation.

As an avid writer about my testicular cancer experiences, I'm sharing my writing process.

During this holiday season, one CURE contributor hopes that others will consider tissue or organ donation.

A panel of caregivers drew upon personal experience to offer advice and ideas to those in this role.

"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.

My son was visibly proud to show me off to his class that day, and I was secretly proud to send his classmates home to talk about poop at the dinner table.

A psychiatrist mom with metastatic breast cancer shares her thoughts about cancer and life in a lovely new book

Many patients with lung cancer may experience side effects, such as fatigue and shortness of breath, that can prevent them from exercising. However, for the first time, new research findings showed benefits from exercise in those with advanced disease.

In this week’s episode of CURE Talks Cancer, we spoke with Jill Kelly – wife of Pro Football Hall of Fame Quarterback Jim Kelly – about his bout with head and neck cancer, and how she copes as a caregiver.

Traveling internationally has its challenges but for those with prosthetics, it's a little more complicated.

Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.

Getting older can be seen as a privilidge.

The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

While I am and will always be a survivor, there are times in life that it should, and will take a back seat.

Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.

When I was diagnosed with Lynch syndrome seven years ago, I began blogging about the roller coaster of emotions I experienced after undergoing genetic testing and prophylactic surgeries.

Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.